https://orcid.org/0000-0003-0673-3654
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aims: This study aimed to retrospectively determine the influence factors and survival effects of chemotherapy in pathological T3N0M0 esophageal cancer (EC) patients based on histological type. Methods: A total of 1136 pathological T3N0M0 EC patients who had surgery were chosen from the Surveillance, Epidemiology and End Results database. The patients were divided into subgroups based on histological type and chemotherapy status. Multivariate logistic regression, log-rank test and Cox regression were used to identify prognostic risk factors and survival differences. A propensity score matching analysis was applied to adjust the covariates. The impact of additional chemotherapy was also assessed in patients who had postoperative radiotherapy. Results: The 5-year overall survival was 36.4% for all patients. Chemotherapy was an independent protective factor of survival in both adenocarcinoma and squamous cell carcinoma patients. In the survival analysis, chemotherapy significantly improved the prognosis of EC patients, both for adenocarcinoma and squamous cell carcinoma. Propensity score matching analysis validated these results. Conclusion: Chemotherapy is recommended for pathological T3N0M0 EC patients regardless of histological type.
Lay abstract
The prognosis of patients with different histological types of esophageal cancer varies. Chemotherapy is important treatment for these patients. However, the survival benefits of chemotherapy with regard to histological type and clinical stage are unclear. Here the authors used a public database to explore the prognostic value of chemotherapy and survival influence factors in these patients.
Supplementary data
To view the supplementary data that accompany this paper, please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2020-1084
Author contributions
Conception, research design, data collection, interpretation and analysis and drafting of the manuscript: X Gu and Y Ge. Data collection, analysis, interpretation and critical revision of the manuscript: J Liu, Q Ding, J Chu and G Tian. Research design, data analysis, result interpretation and writing and critical revision of the manuscript: X Chen. All authors approved the final version and agree to be accountable for all aspects of the work.
Acknowledgments
The authors thank the Surveillance, Epidemiology and End Results program for kindly providing the clinical data. All authors have completed the International Committee of Medical Journal Editors uniform disclosure form.
Disclosure
The authors certify that this manuscript reports the secondary analysis of clinical trial data that have been shared with them and that the use of these shared data is in accordance with the terms (if any) agreed upon on their receipt. The source of these data is the Surveillance, Epidemiology and End Results database. The data the authors used can be downloaded from https://seer.cancer.gov/.
Financial & competing interests disclosure
This work was supported by the Science and Technology Plan Projects of Yangzhou (YZ2020117) and the project of key medical talents of Yangzhou (IDRC 201837). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors are accountable for all aspects of the work, including ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This article does not contain any studies with human participants or animals performed by any of the authors.